View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 4, 2018

Deals this week: IntelGenx, Oasmia Pharmaceutical, Karo Pharma

Canadian oral drug delivery company IntelGenx Technologies plans to issue 300 units priced at $10,000 a unit in a private placement to raise $3m in Canada and the US.

Canadian oral drug delivery company IntelGenx Technologies plans to issue 300 units priced at $10,000 a unit in a private placement to raise $3m in Canada and the US.

Each unit will include 7,940 common shares, 7,690 warrants to buy common shares and $500 convertible notes with an interest rate of 6%. Each warrant can be converted into shares at a price of $0.8 a share.

The company plans to use the proceeds towards phase IIa clinical trial on Montelukast, as well as for working capital.

The company has appointed Cantone Research as placement agent for the transaction.

US-based pharmaceutical company Oasmia Pharmaceutical plans to issue securities in a public offering to raise $25m.

The company plans to use the proceeds from the offering for working capital, research and development (R&D), regulatory affairs, and clinical trial expenditures. The proceeds will also be used for acquisitions, loan repayment and refinancing.

Setterwalls Advokatbyra has been appointed as legal adviser for the transaction.

“US-based pharmaceutical company Oasmia Pharmaceutical plans to issue securities in a public offering to raise $25m.”

Swedish pharmaceutical company Karo Pharma has announced a rights offering of approximately 54.7 million new ordinary shares priced at Skr24 (USD2.76) a share to raise Skr1.31bn ($151.53m).

One subscription right will be allotted to each shareholder, while one ordinary new share will be issued to the holder of two subscription rights.

US-based biopharmaceutical company VIVUS has signed an agreement with Janssen Pharmaceuticals to purchase the rights, title and interest in pancreaze and pancrease MT in the US and Canada, along with related data and intellectual property.

The purchase consideration for the transaction is $135m.

Bristol-Myers Squibb has signed a three-year collaboration extension agreement with Flatiron Health to utilise the latter’s real-world evidence (RWE) data to accelerate R&D efforts and enhance the use of cancer medicines outside of clinical trials.

The two companies also plan to form a joint scientific advisory board on the use of RWE for regulatory decision making.

Based in the US, Bristol-Myers Squibb is a bio-pharmaceutical company, while Flatiron Health, also based in the US, is a healthcare technology and services company.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU